Abstract: An insoluble cell fraction obtained from plant cells cultured in a suspension composed entirely of natural molecules for the treatment of primary and recurrent Clostridium difficile infections is provided. A process for the preparation of the insoluble cell fraction is also provided.

Abstract: The present invention refers to the use of extracts from selected and stabilized cell lines comprising phenylpropanoids with high anti-oxidant capacity having a verbascoside titer of between 20% and 90% and a chromophore-free fraction of between 80% and 10%, in human and veterinary medicine, and for nutritional and cosmetic purposes.

Abstract: The present invention relates to selected and stabilized cell line extracts from Ajuga reptans comprising phenylpropanoids having high antioxidating capacity with a teupolioside titer of between 20% and 90% and a chromophore-free fraction of between 80% and 10%. Said extracts are for use in human and veterinary therapy and for nutritional and cosmetic purposes. Furthermore, the invention relates to a novel phenylpropanoid molecule denominated isoteupolioside.

Abstract: A process for producing a bioreactor using viable immobilized biological material. The process produces a siliceous layer capable of biomass immobilization and selectively cutting off of macromolecules having a molecular weight higher than a selected threshold. The process includes the steps of: (a) supplying a gas flow of a gas carrier saturated by a mixture of silicon alkoxides selected from the group comprising (1) Si(OR)4, (2) SiH(OR)3, (3) R?Si(OR)3 and (4) R?SiH(OR)2 wherein R and R?, equal or different each other, are alkyl and/or aryl groups, wherein said gas flow is prepared by bubbling the gas carrier into a liquid mixture of said alkoxides in the ratio of (1) 40-85/(2) 0-60/(3) 0-60/(4) 0-60 (% v/v), preferably in the ratio of (1) 40-85/(2) 0-50/(3) 0-50/(4) 0-50 (% v/v), more preferably in the ratio of (1) 50-80/(2) 0-20/(3) 5-30/(4) 5-30 (% v/v), at a temperature of from 20 to 180° C., preferably of from 20 to 100° C.

Abstract: The present invention refers to the use of extracts from selected and stabilised cell lines comprising phenylpropanoids with high anti-oxidant capacity having a verbascoside titre of between 20% and 90% and a chromophore-free fraction of between 80% and 10%, in human and veterinary medicine, and for nutritional and cosmetic purposes.

Abstract: The present invention refers to the use of extracts from selected and stabilized cell lines comprising phenylpropanoids with high anti-oxidant capacity having a verbascoside titre of between 20% and 90% and a chromophore-free fraction of between 80% and 10%, in human and veterinary medicine, and for nutritional and cosmetic purposes.

Abstract: Optionally O-substituted glycero-phosphoinositol derivatives, their analogues and their salts wherein the substitutents: R?1, R?2, R2, R3, R4, R5, R6 have the described meaning, their synthesis and their pharmacological effect as modulators of the activation or over-stimulation of cPLA2.

Abstract: A process for producing a bioreactor using viable immobilized biological material. The process produces a siliceous layer capable of biomass immobilization and selectively cutting off of macromolecules having a molecular weight higher than a selected threshold. The process includes the steps of: (a) supplying a gas flow of a gas carrier saturated by a mixture of silicon alkoxides selected from the group comprising (1) Si(OR)4, (2) SiH(OR)3, (3) R?Si(OR)3 and (4) R?SiH(OR)2 wherein R and R?, equal or different each other, are alkyl and/or aryl groups, wherein said gas flow is prepared by bubbling the gas carrier into a liquid mixture of said alkoxides in the ratio of (1) 40-85/(2) 0-60/(3) 0-60/(4) 0-60 (% v/v), preferably in the ratio of (1) 40-85/(2) 0-50/(3) 0-50/(4) 0-50 (% v/v), more preferably in the ratio of (1) 50-80/(2) 0-20/(3) 5-30/(4) 5-30 (% v/v), at a temperature of from 20 to 180° C., preferably of from 20 to 100° C.

Abstract: The present invention relates to a process for producing a bioreactor using viable immobilized biological material and to the bioreactor itself. More particularly, the present invention relates to a process for producing a siliceous layer capable of biomass immobilization and selectively cutting off macromolecules having a molecular weight higher than a selected threshold, comprising the steps of: a) supplying a gas flow of a gas carrier saturated by a mixture of silicon alkoxides selected from the group comprising (1)Si(OR)4, (2)SiH(OR)3, (3)R?Si(OR)3 and (4)R?SiH(OR)2 wherein R and R?, equal or different each other, are alkyl and/or aryl groups, wherein said gas flow is prepared by bubbling the gas carrier into a liquid mixture of said alkoxides in the ratio of (1)40–85/(2)0–60/(3)0–60/(4)0–60 (% v/v), preferably in the ratio of (1)40–85/(2)0–50/(3)0–50/(4)0–50 (% v/v), more preferably in the ratio of (1)50–80/(2)0–20/(3)5–30/(4)5–30 (% v/v), at a temperature of from 20 to 180° C.

Abstract: The present invention relates to selected and stabilized cell line extracts from Ajuga reptans comprising phenylpropanoids having high antioxidating capacity with a teupolioside titre of between 20% and 90% and a chromophore-free fraction of between 80% and 10%. Said extracts are for use in human and veterinary therapy and for nutritional and cosmetic purposes. Furthermore, the invention relates to a novel phenylpropanoid molecule denominated isoteupolioside.

Abstract: The present invention refers to the use of extracts from selected and stabilised cell lines comprising phenylpropanoids with high anti-oxidant capacity having a verbascoside titre of between 20% and 90% and a chromophore-free fraction of between 80% and 10%, in human and veterinary medicine, and for nutritional and cosmetic purposes.

Abstract: The present invention relates to a process for producing a bioreactor using viable immobilized biological material and to the bioreactor itself. More particularly, the present invention relates to a process for producing a siliceous layer capable of biomass immobilization and selectively cutting off macromolecules having a molecular weight higher than a selected threshold, comprising the steps of: a) supplying a gas flow of a gas carrier saturated by a mixture of silicon alkoxides selected from the group comprising (1) Si(OR)4, (2) SiH(OR)3, (3) R?Si(OR)3 and (4) R?SiH(OR)2 wherein R and R?, equal or different each other, are alkyl and/or aryl groups, wherein said gas flow is prepared by bubbling the gas carrier into a liquid mixture of said alkoxides in the ratio of (1) 40-85/(2) 0-60/(3) 0-60/(4) 0-60 (% v/v), preferably in the ratio of (1) 40-85/(2) 0-50/(3) 0-50/(4) 0-50 (% v/v), more preferably in the ratio of (1) 50-80/(2) 0-20/(3) 5-30/(4) 5-30 (% v/v), at a temperature of from 20 to 180° C.

Abstract: A suspension of animal cells is incubated with supports to adhere the cells to the supports. Preferably, the supports have pores that provide pore volume, and the cells are grown during incubation until most of the available pore volume is filled with cells. An encapsulating layer is then formed around the supported cells by exposing the cells on the supports to a reactive gas composed of a carrier gas such as sterile air saturated with an inorganic alkoxide followed by treatment with steam to hydrolyze residual alkoxide groups. The encapsulated cells are stored by immersion in culture media. The cells may be in the form of cell aggregates, and the supports can be sterilized. The supports and encapsulating layer can have pores of a size that permit free exchange nutrients and metabolic products, and excludes the cells from contacting antibodies or immune cells when implanted. The encapsulated cells can used in an extracorporeal device or implanted directly.